Tocilizumab

Where the papers sit

10 papers from the last 6 months study tocilizumab directly · updated from PubMed 1 Nov 2026

• Inflammatory Disease Treatment

  Inflammatory disease treatment centers on optimizing tocilizumab response, safety, and dosing across clinical settings. Rheumatoid arthritis work focuses on infection risk and clinical predictors of response. Pediatric pharmacovigilance adds safety signals, while thyroid eye disease studies compare fixed with weight-based dosing for proptosis. The evidence remains observational, leaving the best dose and patient-selection strategy open.

  4 papers · 40%

• Giant Cell Arteritis Care

  Giant cell arteritis management weighs tocilizumab against glucocorticoid burden and methotrexate combinations. Real-world treatment patterns track persistent steroid exposure and its associated burden. Tocilizumab is linked to fewer major adverse cardiovascular events, while longer-term comparisons address efficacy, relapse control, and serious infections. The central question is how to sustain disease control while reducing glucocorticoid toxicity.

  3 papers · 30%

• Others — Tocilizumab Safety and Applications

  Drug-induced liver injury, Takayasu arteritis, and severe COVID-19 represent distinct clinical uses and complications of tocilizumab. Liver injury is described as an atypical adverse reaction, whereas prolonged treatment is reported in refractory aortitis. In severe COVID-19, comparative analyses examine anakinra, tocilizumab, and in-hospital mortality. Evidence remains case-based or observational, with no unified treatment direction across these conditions.

  3 papers · 30%